A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

NCT02761915 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory Neuroblastoma

Interventions

OTHER: Leukapheresis
DRUG: Cyclophosphamide
DRUG: Fludarabine
GENETIC: 1RG-CART

Sponsor

Cancer Research UK